Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liat Izhak

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Oncoimmunology|June 14, 2013
Balance is a key for happinessLiat Izhak, Jay A Berzofsky, Masaki Terabe
Plos One|April 13, 2018
Correction: Dissecting the Autocrine and Paracrine Roles of the CCR2-CCL2 Axis in Tumor Survival and AngiogenesisLiat Izhak, Gizi Wildbaum, Steffen Jung, et al.
Plos One|January 27, 2012
Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesisLiat Izhak, Gizi Wildbaum, Steffen Jung, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 25, 2018
Correction: Predominant Expression of CCL2 at the Tumor Site of Prostate Cancer Patients Directs a Selective Loss of Immunological Tolerance to CCL2 That Could Be Amplified in a Beneficial MannerLiat Izhak, Gizi Wildbaum, Uri Weinberg, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 10, 2009
Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial mannerLiat Izhak, Gizi Wildbaum, Uri Weinberg, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 19, 2009
A novel recombinant fusion protein encoding a 20-amino acid residue of the third extracellular (E3) domain of CCR2 neutralizes the biological activity of CCL2Liat Izhak, Gizi Wildbaum, Yaniv Zohar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2013
β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergyJessica J O'Konek, Shingo Kato, Satomi Takao, et al.
Cancer Research|January 16, 2013
Delicate balance among three types of T cells in concurrent regulation of tumor immunityLiat Izhak, Elena Ambrosino, Shingo Kato, et al.
Journal for Immunotherapy of Cancer|June 26, 2020
CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cellsAnne W J Martens, Susanne R Janssen, Ingrid A M Derks, et al.
The Journal of Clinical Investigation|January 20, 2011
Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunityJessica J O'Konek, Petr Illarionov, Deborah Stewart Khursigara, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Oncoimmunology|June 14, 2013
Balance is a key for happinessLiat Izhak, Jay A Berzofsky, Masaki Terabe
Plos One|April 13, 2018
Correction: Dissecting the Autocrine and Paracrine Roles of the CCR2-CCL2 Axis in Tumor Survival and AngiogenesisLiat Izhak, Gizi Wildbaum, Steffen Jung, et al.
Plos One|January 27, 2012
Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesisLiat Izhak, Gizi Wildbaum, Steffen Jung, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 25, 2018
Correction: Predominant Expression of CCL2 at the Tumor Site of Prostate Cancer Patients Directs a Selective Loss of Immunological Tolerance to CCL2 That Could Be Amplified in a Beneficial MannerLiat Izhak, Gizi Wildbaum, Uri Weinberg, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 10, 2009
Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial mannerLiat Izhak, Gizi Wildbaum, Uri Weinberg, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 19, 2009
A novel recombinant fusion protein encoding a 20-amino acid residue of the third extracellular (E3) domain of CCR2 neutralizes the biological activity of CCL2Liat Izhak, Gizi Wildbaum, Yaniv Zohar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2013
β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergyJessica J O'Konek, Shingo Kato, Satomi Takao, et al.
Cancer Research|January 16, 2013
Delicate balance among three types of T cells in concurrent regulation of tumor immunityLiat Izhak, Elena Ambrosino, Shingo Kato, et al.
Journal for Immunotherapy of Cancer|June 26, 2020
CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cellsAnne W J Martens, Susanne R Janssen, Ingrid A M Derks, et al.
The Journal of Clinical Investigation|January 20, 2011
Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunityJessica J O'Konek, Petr Illarionov, Deborah Stewart Khursigara, et al.
Pageof 2